Consensus is $9.31. Raises FY revenue growth view to (5.5%)-(3.5%) from (7%)-(4.5%). The outlook is being increased to primarily reflect improved net bookings in the DSA segment during the first quarter, which are expected to result in incremental DSA revenue this year, particularly during the first half.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River reaches settlement with Elliott, to add 4 directors, Reuters says
- CRL Upcoming Earnings Report: What to Expect?
- Charles River price target raised to $118 from $101 at Baird
- Charles River price target lowered to $150 from $185 at BofA
- Charles River Labs: Hold Rating Amid Uncertain R&D Growth and FDA Policy Impact